Thymosin Alpha-1 vs. Thymalin: Choosing the Right Immune Modulator
Both Thymosin Alpha-1 and Thymalin are derived from the thymus, but they differ fundamentally in characterisation, evidence quality, and clinical use. Mechanisms, evidence, protocols, and when to use each.
Evidence strength
Level 3
Case-control study
Peer-reviewed refs
3
Reading time
11 min
Key Takeaways
- Thymosin Alpha-1 is a pure, fully characterised peptide with Phase 2/3 clinical data — approved in 40+ countries as Zadaxin.
- Thymalin is a crude thymic polypeptide extract with strong Russian longevity trial data but lower characterisation certainty.
- The combination appears in community longevity protocols — Tα1 for specific T-cell signalling, Thymalin for broader thymic peptide effects. No trial has tested the two together.
- Thymalin's evidence comes primarily from Russian-language publications with smaller sample sizes. Western validation is limited.
Why the Thymus Matters for Longevity
The thymus — a bilobed lymphoid organ behind the sternum — reaches peak mass at puberty and involutes progressively thereafter, losing roughly 3% of functional tissue per year. By age 65, over 80% is adipose tissue. This thymic involution is a primary driver of immunosenescence: declining T-cell diversity, reduced vaccine response, increased cancer risk, and the systemic inflammatory state (inflammaging) that accelerates ageing.
Both Thymosin Alpha-1 and Thymalin attempt to restore what thymic involution takes away — but through different means.
Thymosin Alpha-1: The Characterised Peptide
Tα1 (28 amino acids, N-terminally acetylated) was isolated by Allan Goldstein's team in the 1970s and is now synthetically manufactured as the drug Zadaxin. It is approved in 40+ countries for:
[1]- Hepatitis B adjuvant therapy
- Hepatitis C in combination with interferon
- Immunocompromised patients (chemotherapy, organ transplant)
- Malignant melanoma (as immune enhancer)
The mechanism is specific: Tα1 binds TLR-2 and TLR-9 on dendritic cells and T-cells, promoting T-cell maturation, Th1 polarisation, NK cell activation, and dendritic cell function. This is a characterised, defined pharmacological interaction.
COVID-19 data: A 2021 retrospective study of 76 severe COVID-19 patients found Tα1 treatment was associated with 28-day mortality of 11% versus 31% in controls — a striking signal that prompted widespread interest. While retrospective and non-randomised, the result is consistent with mechanistic predictions.
Thymalin: The Broad Extract
Thymalin is a polypeptide extract from bovine thymus — containing Tα1 and multiple other thymic peptides (Thymosin β-4, thymopoietin fragments, thymulin, and others). It is not a single characterised compound but a biological mixture.
The St. Petersburg Institute of Bioregulation and Gerontology has conducted the most extensive thymalin research. Its landmark study followed 266 elderly and older people over 6–8 years, with the peptides given during the first 2–3 years of observation.
[2] Patients receiving annual thymalin + epithalon courses showed:
- A 2.0–2.1-fold lower mortality rate in the thymalin group versus controls, and 2.5-fold lower with thymalin plus epithalamin
- A 2.0–2.4-fold drop in acute respiratory disease incidence, plus fewer clinical manifestations of ischaemic heart disease, hypertension, osteoarthrosis and osteoporosis
- In a subgroup given thymalin plus epithalamin annually for 6 years, mortality was 4.1-fold lower than controls
These are compelling numbers — but the headline results come from a mixed intervention (thymalin + epithalamin), the design was open and non-randomised, and there has been no Western replication.
Side-by-Side Comparison
| Feature | Thymosin Alpha-1 | Thymalin |
|---|---|---|
| Structure | Pure 28-aa peptide | Crude polypeptide extract |
| Dose | 1.6mg SC | 10mg IM |
| Evidence level | Phase 2/3 RCTs | Observational, Russian literature |
| Approvals | 40+ countries | Russia, Eastern Europe |
| Mechanism | Specific TLR2/9 agonism | Broad thymic peptide complex |
| Best for | Specific immune modulation | Broader thymic rejuvenation |
When to Use Each
Thymosin Alpha-1 alone: Acute viral infection, post-chemotherapy immune restoration, vaccine enhancement, specific Th1/NK axis support.
Thymalin alone: Longevity protocols following the St. Petersburg bioregulator framework, general age-related immunosenescence, cost-conscious approach.
Combination: Advanced longevity protocols seeking both specific (Tα1) and broad (thymalin) thymic restoration. No trial has tested the two together; this is a community practice.
Practical Protocol
Thymosin Alpha-1: 1.6mg SC, twice weekly (Monday/Thursday). 6–12 week cycles.
Thymalin: 10mg IM, once daily for 10 days. Repeat 2x/year.
Both can be combined by dosing in separate injection sites. Quarterly immune panel monitoring (T-cell subsets, NK activity, CD4/CD8 ratio) is ideal for tracking response.
Related Substances
Scientific References
- [1]Iino S, Toyota J, Kumada H, et al.. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial — Journal of Viral Hepatitis (2005)Oxford 1bPMID 15850471
- [2]Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life — Neuro Endocrinology Letters (2003)Oxford 3PMID 14523363
- [3]Romani L, Bistoni F, Montagnoli C, et al.. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance — Annals of the New York Academy of Sciences (2007)Oxford 5PMID 17495242
Follow us on Google Search
Add BiohackingHub as a preferred source to see more of our research in Google results.
Related protocols
Partner with BiohackingHub
Editorial placements, sponsorships, and product features for evidence-minded brands.